Key points are not available for this paper at this time.
Introduction 5% body weight. Overall, participants benefited from the program with a decrease in BMI of 1.4 kg/m2 (95% CI -1.0, -1.7, P0.01) and body weight loss of 8 lbs (95% CI -6, -10, P0.01). Conclusions: We successfully designed and implemented a comprehensive group care model for overweight/obesity which resulted in reduction in weight and BMI. The model was implemented in a real-world high-volume ambulatory endocrinology setting. Disclosure R. Gorodeski Baskin: None. B. Hatipoglu: Research Support; Tandem Diabetes Care, Inc. I. Neeland: Speaker's Bureau; Boehringer-Ingelheim. Consultant; Eli Lilly and Company. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Bayer Inc. Consultant; Nestlé Health Science. N.J. Bellini: Speaker's Bureau; Abbott. Advisory Panel; Medtronic. Speaker's Bureau; Sanofi. Consultant; embecta. Speaker's Bureau; MannKind Corporation. Advisory Panel; LifeScan Diabetes Institute. Consultant; Insulet Corporation. J.E. Blanchette: Speaker's Bureau; Insulet Corporation. Board Member; Juvenile Diabetes Research Foundation (JDRF). Research Support; American Heart Association, Association of Diabetes Care LifeScan Diabetes Institute. Consultant; WellDoc. Advisory Panel; Cardinal Health/Edgepark. J. Tribout: None. R.C. Katona: None. E. Gorodeski: Consultant; Boston Scientific Corporation. Other Relationship; Dynamed Plus.
Baskin et al. (Fri,) studied this question.